Security
Aura Biosciences, Inc. Common Stock · AURA
AURANASDAQCommon stockCurrentCIK 1501796Updated Oct 28, 2026
AURA price & chart
Loading TradingView…
NASDAQ:AURA on TradingView ↗About the company
Aura Biosciences is a clinical-stage biotechnology company developing bel-sar, a potentially transformative, first-in-class therapy for patients living with ocular cancers. Bel-sar represents an entirely novel approach to treating ocular cancers via its dual mechanisms of action of acute tumor necrosis and secondary anti-tumor immune activation. The Phase 3 registration study of Bel-sar in early choroidal melanoma, the largest patient segment of uveal melanoma, is fully enrolled, and earlier stage studies in metastases to the choroid and cancers of the ocular surface are ongoing. Aura's mission is to improve outcomes for patients living with ocular cancers by delivering a therapy that not only arrests tumor growth but also preserves vision and quality of life.
In the news
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors ↗
Recent filings
SCHEDULE 13G - filed by BlackRock, Inc. regarding Aura Biosciences, Inc.
4 filing
4 filing
S-8 filing
EFFECT filing
Show 5 more recent filings
SCHEDULE 13G - filed by Long Focus Capital Management, LLC regarding Aura Biosciences, Inc.
SCHEDULE 13G/A - filed by Adage Capital Management, L.P. regarding Aura Biosciences, Inc.
S-3 filing
10-Q filing
Results of Operations and Financial Condition · Costs Associated with Exit or Disposal Activities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 2.02, 2.05, 5.02, 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 190,024,000Source | 205,340,000Source | 348,129,000Source | 204,397,000Source | 218,282,000Source | 137,677,000Source | 155,401,000Source | 235,025,000Source | 169,430,000Source | 182,503,000Source | 255,075,000Source | 223,935,000Source |
| Property, Plant and Equipment, NetUSD | 2,629,000Source | 3,325,000Source | 2,201,000Source | 2,864,000Source | 3,334,000Source | 2,472,000Source | 3,111,000Source | 3,054,000Source | 2,624,000Source | 3,215,000Source | 3,150,000Source | 5,371,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 47,553,000Source | 25,407,000Source | 67,836,000Source | 107,367,000Source | 30,075,000Source | 84,793,000Source | 38,226,000Source | 26,279,000Source | 59,515,000Source | 31,693,000Source | 41,063,000Source | 121,582,000Source |
| Assets, CurrentUSD | 170,120,000Source | 183,481,000Source | 329,028,000Source | 183,958,000Source | 195,596,000Source | 118,504,000Source | 134,517,000Source | 212,249,000Source | 149,739,000Source | 160,623,000Source | 231,794,000Source | 196,702,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 8,254,000Source | 9,104,000Source | 5,188,000Source | 6,647,000Source | 8,180,000Source | 3,771,000Source | 6,526,000Source | 9,375,000Source | 5,498,000Source | 9,529,000Source | 5,625,000Source | 7,871,000Source |
| Operating Lease, Right-of-Use AssetUSD | 16,230,000Source | 17,744,000Source | 14,993,000Source | 16,622,000Source | 18,141,000Source | 15,416,000Source | 17,005,000Source | 18,501,000Source | 15,828,000Source | 17,379,000Source | 18,854,000Source | 20,671,000Source |
| Other Assets, NoncurrentUSD | 277,000Source | 22,000Source | 1,139,000Source | 185,000Source | 443,000Source | 517,000Source | 0Source | 453,000Source | 471,000Source | 518,000Source | 509,000Source | 423,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 33,357,000Source | 30,672,000Source | 32,862,000Source | 29,768,000Source | 26,828,000Source | 30,430,000Source | 27,435,000Source | 26,242,000Source | 32,517,000Source | 30,533,000Source | 29,227,000Source | 28,352,000Source |
| Stockholders’ equity: | ||||||||||||
| Additional Paid in CapitalUSD | 611,457,000Source | 522,454,000Source | 914,769,000Source | 603,333,000Source | 518,988,000Source | 621,557,000Source | 529,571,000Source | 515,779,000Source | 617,433,000Source | 525,934,000Source | 512,617,000Source | 406,555,000Source |
| Retained Earnings (Accumulated Deficit)USD | -454,859,000Source | -348,393,000Source | -559,740,000Source | -428,729,000Source | -327,351,000Source | -514,103,000Source | -401,710,000Source | -307,014,000Source | -480,418,000Source | -374,227,000Source | -287,308,000Source | -210,900,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 69,000Source | 607,000Source | -670,000Source | 25,000Source | -183,000Source | -207,000Source | 105,000Source | 18,000Source | -102,000Source | 263,000Source | 539,000Source | -72,000Source |
| Stockholders' Equity Attributable to ParentUSD | 156,667,000Source | 174,668,000Source | 315,267,000Source | 174,629,000Source | 191,454,000Source | 107,247,000Source | 127,966,000Source | 208,783,000Source | 136,913,000Source | 151,970,000Source | 225,848,000Source | 195,583,000Source |
| Liabilities and EquityUSD | 190,024,000Source | 205,340,000Source | 348,129,000Source | 204,397,000Source | 218,282,000Source | 137,677,000Source | 155,401,000Source | 235,025,000Source | 169,430,000Source | 182,503,000Source | 255,075,000Source | 223,935,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 18,823,000Source | 14,714,000Source | 19,560,000Source | 14,852,000Source | 10,548,000Source | 16,706,000Source | 12,163,000Source | 9,663,000Source | 18,383,000Source | 14,913,000Source | 12,357,000Source | 10,457,000Source |
| Operating Lease, Liability, CurrentUSD | 3,220,000Source | 3,126,000Source | 3,292,000Source | 3,196,000Source | 2,754,000Source | 3,267,000Source | 3,172,000Source | 2,741,000Source | 3,243,000Source | 3,149,000Source | 2,687,000Source | 2,963,000Source |
| Accounts Payable, CurrentUSD | 1,888,000Source | 1,991,000Source | 2,254,000Source | 1,286,000Source | 1,459,000Source | 2,573,000Source | 2,006,000Source | 1,933,000Source | 1,549,000Source | 2,304,000Source | 1,787,000Source | 2,921,000Source |
| Operating Lease, Liability, NoncurrentUSD | 14,534,000Source | 15,958,000Source | 13,302,000Source | 14,916,000Source | 16,280,000Source | 13,724,000Source | 15,272,000Source | 16,579,000Source | 14,134,000Source | 15,620,000Source | 16,870,000Source | 17,895,000Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | 144,200,000Source | — | — | 188,800,000Source |
| Common Stock, Value, Issued | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -33,685,000Source | -27,483,000Source | -106,191,000Source | -86,919,000Source | -76,408,000Source | -58,763,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 3,824,000Source | 3,514,000Source | 14,317,000Source | 11,722,000Source | 8,772,000Source | 6,412,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 1,024,000Source | -298,000Source | -846,000Source | 482,000Source | -1,040,000Source | 340,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -29,893,000Source | -23,355,000Source | -84,742,000Source | -79,805,000Source | -63,847,000Source | -54,601,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 54,898,000Source | 29,813,000Source | 35,595,000Source | 68,821,000Source | -113,963,000Source | -67,869,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 102,000Source | 187,000Source | 447,000Source | 1,253,000Source | 709,000Source | 1,094,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 300,000Source | 96,000Source | 77,155,000Source | 1,595,000Source | 97,290,000Source | 95,629,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | — | — | -9,389,000Source | -80,520,000Source | -26,841,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 48,321,000Source | 26,175,000Source | 68,604,000Source | 108,135,000Source | 85,561,000Source | 38,994,000Source | 60,283,000Source | 32,461,000Source | 41,850,000Source | 122,370,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 100,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 3,688,000Source | 2,750,000Source | 12,368,000Source | 3,833,000Source | 3,824,000Source | 3,514,000Source | 14,317,000Source | 11,722,000Source | 8,772,000Source | 6,412,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | 144,200,000Source | — | — | 188,800,000Source |
| DepreciationUSD | — | — | 300,000Source | 300,000Source | 300,000Source | 300,000Source | 274,000Source | 291,000Source | 1,129,000Source | 1,223,000Source | 1,295,000Source | 1,177,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | — | — | 208,000Source | -318,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | -9,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | 0Source | -208,000Source | 22,000Source |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | — | — | — | — | — | — | — | — | -296,000Source |
| General and Administrative ExpenseUSD | — | — | 5,728,000Source | 6,196,000Source | 17,320,000Source | 5,731,000Source | 6,906,000Source | 5,692,000Source | 22,491,000Source | 22,814,000Source | 19,759,000Source | 18,057,000Source |
| Income Tax Expense (Benefit)USD | — | — | 26,000Source | 43,000Source | 29,000Source | 48,000Source | 11,000Source | 18,000Source | 108,000Source | 112,000Source | 137,000Source | 0Source |
| Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | — | — | — | — | — | 292,000Source | 501,000Source | 1,546,000Source | 4,659,000Source | 3,992,000Source | 527,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -26,130,000Source | -21,042,000Source | -45,637,000Source | -27,019,000Source | -33,685,000Source | -27,483,000Source | -106,191,000Source | -86,919,000Source | -76,408,000Source | -58,763,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,802,000Source | 2,233,000Source | 2,461,000Source | 1,642,000Source | 1,192,000Source | 1,570,000Source | 6,708,000Source | 9,309,000Source | 8,720,000Source | 1,532,000Source |
| Operating Costs and ExpensesUSD | — | — | 27,906,000Source | 23,232,000Source | 48,069,000Source | 28,613,000Source | 34,866,000Source | 29,035,000Source | 112,791,000Source | 96,116,000Source | 84,991,000Source | 60,295,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -13,000Source | -25,000Source | 154,000Source | -36,000Source | 2,000Source | -24,000Source | 77,000Source | -120,000Source | -76,000Source | -5,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 46,517,000Source | — | — | 86,650,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 56,000Source | 0Source | 1,010,000Source | 1,418,000Source | 1,376,000Source | 430,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -27,906,000Source | -23,232,000Source | -48,069,000Source | -28,613,000Source | -34,866,000Source | -29,035,000Source | -112,791,000Source | -96,116,000Source | -84,991,000Source | -60,295,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -13,000Source | -25,000Source | 154,000Source | -36,000Source | 2,000Source | -24,000Source | 77,000Source | -120,000Source | -76,000Source | -5,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -26,104,000Source | -20,999,000Source | -45,608,000Source | -26,971,000Source | -33,674,000Source | -27,465,000Source | -106,083,000Source | -86,807,000Source | -76,271,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | 26,000Source | 43,000Source | 29,000Source | 48,000Source | 11,000Source | 18,000Source | 108,000Source | 112,000Source | 137,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -26,130,000Source | -21,042,000Source | -45,637,000Source | -27,019,000Source | -33,685,000Source | -27,483,000Source | -106,191,000Source | -86,919,000Source | -76,408,000Source | -58,763,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.4Source | -0.42Source | -0.48Source | -0.47Source | -0.5Source | -0.55Source | -1.76Source | -1.75Source | -1.93Source | -1.96Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.4Source | -0.42Source | -0.48Source | -0.47Source | -0.5Source | -0.55Source | -1.76Source | -1.75Source | -1.93Source | -1.96Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 65,936,672Source | 49,663,532Source | 94,863,400Source | 58,015,718Source | 67,447,576Source | 50,126,148Source | 60,337,608Source | 49,650,480Source | 39,620,036Source | 29,937,228Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 65,936,672Source | 49,663,532Source | 94,863,400Source | 58,015,718Source | 67,447,576Source | 50,126,148Source | 60,337,608Source | 49,650,480Source | 39,620,036Source | 29,937,228Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 108,000Source | 112,000Source | 137,000Source | — |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | -9,000Source |
| General and Administrative ExpenseUSD | — | — | 5,728,000Source | 6,196,000Source | 17,320,000Source | 5,731,000Source | 6,906,000Source | 5,692,000Source | 22,491,000Source | 22,814,000Source | 19,759,000Source | 18,057,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -106,911,000Source | -86,185,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 1,802,000Source | 2,233,000Source | 2,461,000Source | 1,642,000Source | 1,192,000Source | 1,570,000Source | 6,708,000Source | 9,309,000Source | 8,720,000Source | 1,532,000Source |
| Operating Costs and ExpensesUSD | — | — | 27,906,000Source | 23,232,000Source | 48,069,000Source | 28,613,000Source | 34,866,000Source | 29,035,000Source | 112,791,000Source | 96,116,000Source | 84,991,000Source | 60,295,000Source |
| Research and Development ExpenseUSD | — | — | 22,178,000Source | 17,036,000Source | 30,749,000Source | 22,882,000Source | 27,960,000Source | 23,343,000Source | 90,300,000Source | 73,302,000Source | 65,232,000Source | 42,238,000Source |
Offerings
Registration 333-298228
Registration 333-295515
Filing attachments
d140546dex41.htm · S-3 · 2026-08-11
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The summary of the general terms and provisions of the registered securities of Aura Biosciences, Inc. (the “Company,” “we,” “us,” and “our”) set forth below does not purport to be complete. It is subject to and qualified in its entirety by reference to our Tenth Amended and Restated Certificate of Incorporation, as amended (“certificate of incorporation”), our Amen…
Read attachment ↗aura-ex99_1.htm · 8-K · 2026-08-11
EX-99.1 2 aura-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights Phase 3 CoMpass trial fully enrolled with 108 patients, exceeding enrollment target; on track for topline data in 2H 2027 Strategic operating plan refined to focus on development of bel-sar in ocular oncology Interim NMIBC data reinforce bel-sar’s potential for durable efficacy and favorable safety profile; NMIBC program being strategically…
Read attachment ↗aura-ex99_2.htm · 8-K · 2026-08-11
EX-99.2 3 aura-ex99_2.htm EX-99.2 August 2026 Exhibit 99.2 Legal Disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking words such as "may", "anticipate", "believe", "could', "expect", "should", "plan", "intend", "estimate", "will", "potential" and "ongoing", among others, although not all forward-lookin…
Read attachment ↗aura-ex99_1.htm · 8-K · 2026-07-08
EX-99.1 3 aura-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aura Biosciences Announces Appointment of Jeremy Bender, Ph. D., M.B.A., to Board of Directors BOSTON, MA - July 8, 2026 - Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Jeremy Bender, Ph. D., M.B.A., to its Board of Directors. “I am thrilled to welcome Jeremy to our Board of Directors…
Read attachment ↗d118275dex991.htm · S-8 · 2026-05-19
EXHIBIT 99.1 AURA BIOSCIENCES, INC. RESTRICTED STOCK UNIT AWARD AGREEMENT (INDUCEMENT AWARD) Name of Grantee: No. of Restricted Stock Units: Grant Date: Aura Biosciences, Inc. (the “Company”) hereby grants an award of the number of Restricted Stock Units listed above (an “Award”) to the Grantee named above. Each Restricted Stock Unit shall relate to one share of Common Stock, par value $0.00001 per share (the “Stock”), of the Company. This Award is not issued under the Aura Bioscience…
Read attachment ↗d118275dex992.htm · S-8 · 2026-05-19
Exhibit 99.2 AURA BIOSCIENCES, INC. NON-QUALIFIED STOCK OPTION AGREEMENT (INDUCEMENT AWARD) Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ [FMV on Grant Date] Grant Date: Vesting Commencement Date: Expiration Date: [No more than 10 years] Aura Biosciences, Inc. (the “Company”) hereby grants to the Optionee named above an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of …
Read attachment ↗